Phospho-specific flow cytometry identifies aberrant signaling in indolent B-cell lymphoma

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Blix, Egil S ^a,b   Irish, Jonathan M ^c,d   Husebekk, Anne ^a   Delabie, Jan ^e   Forfang, Lise ^e   Tierens, Anne M ^e   Myklebust, June H ^e   Kolstad, Arne ^f  

^a UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d STANFORD UNIVERSITY   (United States)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

^f OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

B cell lymphoma; B cell receptor; CD40; Cell signaling; Phospho flow cytometry

Indexed keywords

B LYMPHOCYTE RECEPTOR; CD20 ANTIGEN; CD40 LIGAND; CD5 ANTIGEN; CD79B ANTIGEN; IMMUNOGLOBULIN M; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 7; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHOLIPASE C GAMMA; PROTEIN MCL 1; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE; STAT5 PROTEIN; STAT6 PROTEIN; TRANSCRIPTION FACTOR RELA;

ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CELL SURFACE; CELL SUSPENSION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRACELLULAR SIGNALING; MARGINAL ZONE LYMPHOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN CROSS LINKING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SMALL CELL LYMPHOCYTIC LYMPHOMA; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE;

ANTIGENS, CD40; ANTIGENS, CD79; CD40 LIGAND; CLUSTER ANALYSIS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLOW CYTOMETRY; HUMANS; INTERLEUKINS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, B-CELL; LYMPHOMA, B-CELL, MARGINAL ZONE; MODELS, BIOLOGICAL; PHOSPHOLIPASE C GAMMA; PHOSPHOPROTEINS; PHOSPHORYLATION; RECEPTORS, ANTIGEN, B-CELL; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR; STAT6 TRANSCRIPTION FACTOR; T-LYMPHOCYTES; TRANSCRIPTION FACTOR RELA;

EID: 84867411512     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-478     Document Type: Article

References (52)

1. Zenz T, Mertens D, Kuppers R, Dohner H, Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 2010, 10(1):37-50.
2. Kuppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer 2005, 5(4):251-262. 10.1038/nrc1589, 15803153.
3. Niiro H, Clark EA. Regulation of B-cell fate by antigen-receptor signals. Nat Rev Immunol 2002, 2(12):945-956. 10.1038/nri955, 12461567.
4. Takata M, Sabe H, Hata A, Inazu T, Homma Y, Nukada T, Yamamura H, Kurosaki T. Tyrosine kinases Lyn and Syk regulate B cell receptor-coupled Ca2+ mobilization through distinct pathways. EMBO J 1994, 13(6):1341-1349. 394950, 8137818.
5. Mackay F, Figgett WA, Saulep D, Lepage M, Hibbs ML. B-cell stage and context-dependent requirements for survival signals from BAFF and the B-cell receptor. Immunol Rev 2010, 237(1):205-225. 10.1111/j.1600-065X.2010.00944.x, 20727038.
6. Packham G, Stevenson F. The role of the B-cell receptor in the pathogenesis of chronic lymphocytic leukaemia. Semin Cancer Biol 2010, 20(6):391-399. 10.1016/j.semcancer.2010.08.004, 20816790.
7. Pleyer L, Egle A, Hartmann TN, Greil R. Molecular and cellular mechanisms of CLL: novel therapeutic approaches. Nat Rev Clin Oncol 2009, 6(7):405-418. 10.1038/nrclinonc.2009.72, 19488076.
8. Graham JP, Arcipowski KM, Bishop GA. Differential B-lymphocyte regulation by CD40 and its viral mimic, latent membrane protein 1. Immunol Rev 2010, 237(1):226-248. 10.1111/j.1600-065X.2010.00932.x, 20727039.
9. Ranheim EA, Kipps TJ. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med 1993, 177(4):925-935. 10.1084/jem.177.4.925, 2190967, 7681471.
10. Berberich I, Shu G, Clark E. Cross-linking CD40 on B cells rapidly activates nuclear factor-kappa B. J Immunol 1994, 153(10):4357-4366.
11. Lalmanach-Girard AC, Chiles TC, Parker DC, Rothstein TL. T cell-dependent induction of NF-kappa B in B cells. J Exp Med 1993, 177(4):1215-1219. 10.1084/jem.177.4.1215, 2190960, 8459216.
12. Cuni S, Perez-Aciego P, Perez-Chacon G, Vargas JA, Sanchez A, Martin-Saavedra FM, Ballester S, Garcia-Marco J, Jorda J, Durantez A. A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells. Leukemia 2004, 18(8):1391-1400. 10.1038/sj.leu.2403398, 15175625.
13. Gricks CS, Zahrieh D, Zauls AJ, Gorgun G, Drandi D, Mauerer K, Neuberg D, Gribben JG. Differential regulation of gene expression following CD40 activation of leukemic compared to healthy B cells. Blood 2004, 104(13):4002-4009. 10.1182/blood-2004-02-0494, 15161673.
14. Kater AP, Evers LM, Remmerswaal EBM, Jaspers A, Oosterwijk MF, van Lier RAW, van Oers MHJ, Eldering E. CD40 stimulation of B-cell chronic lymphocytic leukaemia cells enhances the anti-apoptotic profile, but also Bid expression and cells remain susceptible to autologous cytotoxic T-lymphocyte attack. Br J Haematol 2004, 127(4):404-415. 10.1111/j.1365-2141.2004.05225.x, 15521917.
15. Romano MF, Lamberti A, Tassone P, Alfinito F, Costantini S, Chiurazzi F, Defrance T, Bonelli P, Tuccillo F, Turco MC, et al. Triggering of CD40 Antigen Inhibits Fludarabine-Induced Apoptosis in B Chronic Lymphocytic Leukemia Cells. Blood 1998, 92(3):990-995.
16. Sutherland C, Heath A, Pelech S, Young P, Gold M. Differential activation of the ERK, JNK, and p38 mitogen-activated protein kinases by CD40 and the B cell antigen receptor. J Immunol 1996, 157(8):3381-3390.
17. Decker T, Schneller F, Hipp S, Miething C, Jahn T, Duyster J, Peschel C. Cell cycle progression of chronic lymphocytic leukemia cells is controlled by cyclin D2, cyclin D3, cyclin-dependent kinase (cdk) 4 and the cdk inhibitor p27. Leukemia 2002, 16(3):327-334. 10.1038/sj.leu.2402389, 11896535.
18. Ayanlar-Batuman O, Ebert E, Hauptman S. Defective interleukin-2 production and responsiveness by T cells in patients with chronic lymphocytic leukemia of B cell variety. Blood 1986, 67(2):279-284.
19. Rossmann ED, Lewin N, Jeddi-Tehrani M, Osterborg A, Mellstedt H. Intracellular T cell cytokines in patients with B cell chronic lymphocytic leukaemia (B-CLL). Eur J Haematol 2002, 68(5):299-306. 10.1034/j.1600-0609.2002.01612.x, 12144536.
20. Irish JM, Czerwinski DK, Nolan GP, Levy R. Kinetics of B cell receptor signaling in human B cell subsets mapped by phosphospecific flow cytometry. J Immunol 2006, 177(3):1581-1589.
21. Irish JM, Czerwinski DK, Nolan GP, Levy R. Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells. Blood 2006, 108(9):3135-3142. 10.1182/blood-2006-02-003921, 1895530, 16835385.
22. Irish JM, Myklebust JH, Alizadeh AA, Houot R, Sharman JP, Czerwinski DK, Nolan GP, Levy R. B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression. Proc Natl Acad Sci U S A 2010, 107(29):12747-12754. 10.1073/pnas.1002057107, 2919949, 20543139.
23. Krutzik PO, Nolan GP. Intracellular phospho-protein staining techniques for flow cytometry: Monitoring single cell signaling events. Cytometry A 2003, 55A(2):61-70.
24. Irish JM, Kotecha N, Nolan GP. Mapping normal and cancer cell signalling networks: towards single-cell proteomics. Nat Rev Cancer 2006, 6(2):146-155. 10.1038/nrc1804, 16491074.
25. Swerdlow SH, International Agency for Research on Cancer WHO classification of tumours of haematopoietic and lymphoid tissue 2008, Lyon: IARC, 4, International Agency for Research on Cancer.
26. Krutzik PO, Nolan GP. Fluorescent cell barcoding in flow cytometry allows high-throughput drug screening and signaling profiling. Nat Methods 2006, 3(5):361-368. 10.1038/nmeth872, 16628206.
27. Cluster 3.0. http://bonsai.hgc.jp/~mdehoon/software/cluster/software.htm.
28. Java TreeView. http://jtreeview.sourceforge.net/.
29. Petlickovski A, Laurenti L, Li X, Marietti S, Chiusolo P, Sica S, Leone G, Efremov DG. Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells. Blood 2005, 105(12):4820-4827. 10.1182/blood-2004-07-2669, 15728130.
30. Younes A, Fanale MA, McLaughlin P, Copeland A, Zhu J, de Castro Faria S. Phase I Study of a Novel Oral JAK-2 Inhibitor SB1518 In Patients with Relapsed Lymphoma: Evidence of Clinical and Biologic Activity In Multiple Lymphoma Subtypes. ASH Annual Meeting Abstracts 2010, 116(21):2830.
31. Hart S, Goh KC, Novotny-Diermayr V, Hu CY, Hentze H, Tan YC, Madan B, Amalini C, Loh YK, Ong LC, et al. SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies. Leukemia 2011, 25(11):1751-1759. 10.1038/leu.2011.148, 21691275.
32. Muzio M, Apollonio B, Scielzo C, Frenquelli M, Vandoni I, Boussiotis V, Caligaris-Cappio F, Ghia P. Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy. Blood 2008, 112(1):188-195. 10.1182/blood-2007-09-111344, 18292287.
33. Poggi A, Catellani S, Bruzzone A, Caligaris-Cappio F, Gobbi M, Zocchi MR. Lack of the leukocyte-associated Ig-like receptor-1 expression in high-risk chronic lymphocytic leukaemia results in the absence of a negative signal regulating kinase activation and cell division. Leukemia 2008, 22(5):980-988. 10.1038/leu.2008.21, 18288129.
34. Contri A, Brunati AM, Trentin L, Cabrelle A, Miorin M, Cesaro L, Pinna LA, Zambello R, Semenzato G, Donella-Deana A. Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. J Clin Invest 2005, 115(2):369-378. 544036, 15650771.
35. Gobessi S, Laurenti L, Longo PG, Carsetti L, Berno V, Sica S, Leone G, Efremov DG. Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells. Leukemia 2009, 23(4):686-697. 10.1038/leu.2008.346, 19092849.
36. Lanham S, Hamblin T, Oscier D, Ibbotson R, Stevenson F, Packham G. Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia. Blood 2003, 101(3):1087-1093. 10.1182/blood-2002-06-1822, 12393552.
37. Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, LaCasce A, Schaefer-Cutillo J, De Vos S, Sinha R, Leonard JP, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010, 115(13):2578-2585. 10.1182/blood-2009-08-236471, 2852362, 19965662.
38. Zomas AP, Matutes E, Morilla R, Owusu-Ankomah K, Seon BK, Catovsky D. Expression of the immunoglobulin-associated protein B29 in B cell disorders with the monoclonal antibody SN8 (CD79b). Leukemia 1996, 10(12):1966-1970.
39. Lewis RE, Cruse JM, Pierce S, Lam J, Tadros Y. Surface and cytoplasmic immunoglobulin expression in B-cell chronic lymphocytic leukemia (CLL). Exp Mol Pathol 2005, 79(2):146-150. 10.1016/j.yexmp.2005.04.009, 15963979.
40. Minuzzo S, Indraccolo S, Tosello V, Piovan E, Cabrelle A, Trentin L, Semenzato G, Amadori A. Heterogeneous intracellular expression of B-cell receptor components in B-cell chronic lymphocytic leukaemia (B-CLL) cells and effects of CD79b gene transfer on surface immunoglobulin levels in a B-CLL-derived cell line. Br J Haematol 2005, 130(6):878-889. 10.1111/j.1365-2141.2005.05699.x, 16156858.
41. Vuillier F, Dumas G, Magnac C, Prevost M-C, Lalanne AI, Oppezzo P, Melanitou E, Dighiero G, Payelle-Brogard B. Lower levels of surface B-cell-receptor expression in chronic lymphocytic leukemia are associated with glycosylation and folding defects of the micro and CD79a chains. Blood 2005, 105(7):2933-2940. 10.1182/blood-2004-09-3643, 15591116.
42. Guarini A, Chiaretti S, Tavolaro S, Maggio R, Peragine N, Citarella F, Ricciardi MR, Santangelo S, Marinelli M, De Propris MS, et al. BCR ligation induced by IgM stimulation results in gene expression and functional changes only in IgV H unmutated chronic lymphocytic leukemia (CLL) cells. Blood 2008, 112(3):782-792. 10.1182/blood-2007-12-127688, 18487510.
43. Ian Mockridge C, Potter KN, Wheatley I, Neville LA, Packham G, Stevenson FK. Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status. Blood 2007, 109(10):4424-4431. 10.1182/blood-2006-11-056648, 17255355.
44. Chen L, Huynh L, Apgar J, Tang L, Rassenti L, Weiss A, Kipps TJ. ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia. Blood 2008, 111(5):2685-2692. 10.1182/blood-2006-12-062265, 2254551, 18048647.
45. Laytragoon-Lewin N, Duhony E, Bai XF, Mellstedt H. Downregulation of the CD95 receptor and defect CD40-mediated signal transduction in B-chronic lymphocytic leukemia cells. Eur J Haematol 1998, 61(4):266-271.
46. Pedersen IM, Buhl AM, Klausen P, Geisler CH, Jurlander J. The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism. Blood 2002, 99(4):1314-1319. 10.1182/blood.V99.4.1314, 11830481.
47. Tonino SH, van Laar J, van Oers MH, Wang JY, Eldering E, Kater AP. ROS-mediated upregulation of Noxa overcomes chemoresistance in chronic lymphocytic leukemia. Oncogene 2011, 30(6):701-713. 10.1038/onc.2010.441, 20935673.
48. Hewamana S, Alghazal S, Lin TT, Clement M, Jenkins C, Guzman ML, Jordan CT, Neelakantan S, Crooks PA, Burnett AK, et al. The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. Blood 2008, 111(9):4681-4689. 10.1182/blood-2007-11-125278, 18227347.
49. Wlodarski P, Kasprzycka M, Liu X, Marzec M, Robertson ES, Slupianek A, Wasik MA. Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum. Cancer Res 2005, 65(17):7800-7808.
50. Donahue AC, Fruman DA. Distinct signaling mechanisms activate the target of rapamycin in response to different B-cell stimuli. Eur J Immunol 2007, 37(10):2923-2936. 10.1002/eji.200737281, 17724683.
51. Zent CS, LaPlant BR, Johnston PB, Call TG, Habermann TM, Micallef IN, Witzig TE. The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation. Cancer 2010, 116(9):2201-2207. 2861142, 20166206.
52. Ramsay AG, Johnson AJ, Lee AM, Gorgun G, Le Dieu R, Blum W, Byrd JC, Gribben JG. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 2008, 118(7):2427-2437. 2423865, 18551193.